GlobalRPh RX List - Glycopyrrolate (Robinul), first link
- Product / population
- ROBINUL injectable source; not oral ROBINUL tablets, CUVPOSA, DARTISLA ODT or inhaled products.
- Renal measure
- Renal failure; intravenous pharmacokinetic study.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
In uremic renal-transplant patients, intravenous glycopyrrolate had reduced clearance and urinary recovery and increased exposure compared with controls. The source concludes that renal failure can markedly impair elimination. These findings are pharmacokinetic evidence; they do not define a particular reduced dose or interval. Use only the injectable product's indication-specific instructions, not an oral or inhaled renal regimen.